A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study of the Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Healthy Subjects

Trial Profile

A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study of the Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs AG 10 (Primary)
  • Indications Amyloidosis
  • Focus Adverse reactions; First in man
  • Sponsors Eidos Therapeutics
  • Most Recent Events

    • 28 Sep 2017 According to an Eidos Therapeutics media release, dosing of the first healthy adult cohort has commenced.
    • 22 Sep 2017 Status changed from planning to recruiting.
    • 08 May 2017 According to an BridgeBio Pharma media release, this study is expected to initiate in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top